N-[1]naphthyl-ethanesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[1]naphthyl-ethanesulfonamide
• 英文别名: Aethansulfonsaeure-α-naphthylamid；N-[1]Naphthyl-aethansulfonamid；N-naphthalen-1-ylethanesulfonamide
• 化学式: C₁₂H₁₃NO₂S
• mdl: MFCD03376933
• 分子量: 235.307
• InChiKey: FJJSCXZEHPNMBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080286233A1

  公开（公告）日：2008-11-20

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药学上可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• LUBRICANT COMPOSITION
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：EP2444474A1

  公开（公告）日：2012-04-25

  A lubricant oil composition which is excellent in wear resistance, high temperature detergency and base number retaining property, despite its low phosphorus content, low sulfur content and low sulfuric acid ash content, is provided at a low cost by compounding a sulfonamide compound having a specific structure in a base oil.

  通过在基础油中复合具有特定结构的磺酰胺化合物，以低成本提供了一种尽管磷含量低、硫含量低和硫酸灰分含量低，但却具有优异的耐磨性、高温清净性和基数保持性能的润滑油组合物。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
  申请人：Incyte Holdings Corporation

  公开号：EP2426129B1

  公开（公告）日：2016-11-02